Previous 10 | Next 10 |
2023-03-21 11:49:00 ET Summary Botensilimab is engineered for major improvements over earlier CTLA-4 agents. Melanoma, colorectal and pancreatic cancer Phase 2 trial enrollments should complete in 2023. An application to the FDA for commercial approval could come as early as 2...
2023-03-17 16:16:22 ET Summary Here's a long list of biopharmas exposed to SVB Financial Group. Many of these deposits will be uninsured. However, since SVB Financial Group was quite solvent otherwise, much of these deposits should be recoverable by these small companies. ...
2023-03-15 16:00:28 ET There is extreme volatility in the stock market today, and it isn’t just with penny stocks . Investors are on edge thanks to the contagion spreading from last week’s Silicon Valley Bank implosion, this week’s continued banking industry woes, a...
2023-03-14 09:56:58 ET The immuno-oncology company Agenus ( NASDAQ: AGEN ) opened ~10% higher on Tuesday morning to rise for the second straight session after indicating a sizable topline beat with its Q4 2022 financials and issuing its 2023 objectives. The quarterly rev...
2023-03-14 07:33:54 ET Agenus press release ( NASDAQ: AGEN ): Q4 GAAP EPS of -$0.24 misses by $0.02 . Revenue of $28.39M (+40.1% Y/Y) beats by $10.56M . As of December 31, 2022, we had a cash, cash equivalent and short-term investment balance of $193 million, c...
Botensilimab plus balstilimab showed overall response rates of 23% in microsatellite stable colorectal cancer (MSS CRC), 50% in PD-(L)1 refractory non-small cell lung cancer (NSCLC) and in seven additional metastatic, late-line cancers in a total of more than 300 patients Randomized Phase 2 t...
2023-03-13 13:37:30 ET Agenus ( NASDAQ: AGEN ) is scheduled to announce Q4 earnings results on Tuesday, March 14th, before market open. The consensus EPS Estimate is -$0.22 and the consensus Revenue Estimate is $17.83M (-12.0% Y/Y). Over the last 1 year, AGEN has bea...
LEXINGTON, Mass., March 12, 2023 (GLOBE NEWSWIRE) -- Agenus (Nasdaq: AGEN), a clinical-stage company with a pipeline of therapies designed to activate the body's immune system to fight cancer and infections, today announced that it has cancelled its conference call on Monday, March 13 th ...
LEXINGTON, Mass., March 11, 2023 (GLOBE NEWSWIRE) -- Agenus (Nasdaq: AGEN), a clinical-stage company with a pipeline of therapies designed to activate the body's immune system to fight cancer and infections, today announced that it will hold a conference call to provide detail and to answer a...
LEXINGTON, Mass., Feb. 28, 2023 (GLOBE NEWSWIRE) -- Agenus (Nasdaq: AGEN), an immuno-oncology company with a pipeline of immunological agents targeting cancer and infectious disease, today announced the Company will release its fourth quarter and full year 2022 financial results before the market...
News, Short Squeeze, Breakout and More Instantly...
Extended BOT/BAL Therapy Yields Pronounced Improvements in Tumor Reductions Agenus Inc. (“Agenus”) (Nasdaq: AGEN), a leader in developing novel immunological agents to treat various cancers, today announced results from an investigator-sponsored trial (IST) of botensilim...
Agenus Inc. (“Agenus”) (Nasdaq: AGEN), a leader in developing novel immunological agents to treat various cancers, today announced that the Cancer Therapy Evaluation Program (CTEP) is accepting Letters of Intent (LOIs) to conduct clinical studies using botensilimab (BOT), a huma...
2024-06-27 01:30:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...